Treatment of ANCA-associated vascularitides;Traitement des vascularites systémiques associées aux ANCA

Presse Medicale

Volumn 36, Issue 5 II, 2007, Pages 922-927

  Guillevin, Loïc ^a   Pagnoux, Christian ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; INTERLEUKIN 5; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE;

ALLERGIC PNEUMONITIS; CHURG STRAUSS SYNDROME; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; HYPOPLASIA; LIVER TOXICITY; NEUTROPENIA; SHORT SURVEY; WEGENER GRANULOMATOSIS; BIOLOGICAL THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ANTAGONISM; PLASMAPHERESIS; PROGNOSIS; PROSPECTIVE STUDY; REMISSION; REVIEW; TIME; VASCULITIS;

ADRENAL CORTEX HORMONES; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BIOLOGICAL THERAPY; CHURG-STRAUSS SYNDROME; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-5; METHOTREXATE; PLASMA EXCHANGE; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 34247355579     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.01.029     Document Type: Short Survey

References (30)

1. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., Dadoniene J., et al., European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitisassociated with antineutrophil cytoplasmic antibodies. N Engl J Med 349 (2003) 36-44
2. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116 (1992) 488-498
3. Guillevin L., Durand Gasselin B., Cevallos R., Gayraud M., Lhote F., Callard P., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42 (1999) 421-430
4. Guillevin L., Cohen P., Gayraud M., Lhote F., Jarrousse B., and Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78 (1999) 26-37
5. Guillevin L., Lhote F., Gayraud M., Cohen P., Jarrousse B., Lortholary O., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75 (1996) 17-28
6. Guilpain P., Chanseaud Y., Tamby M.C., Mahr A., Servettaz A., Guillevin L., et al. Pathogénie des vascularites systémiques primitives (I): Les vascularites ANCA positives. Presse Med 34 (2005) 1013-1022
7. Guillevin L., and Pagnoux C. When should immunosuppressants be prescribed to treat systemic vasculitides?. Intern Med 42 (2003) 313-317
8. Guillevin L., Cordier J., Lhote F., Cohen P., Jarrousse B., Royer I., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40 (1997) 2187-2198
9. Nachman P.H., Hogan S.L., Jennette J.C., and Falk R.J. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7 (1996) 33-39
10. Adu D., Pall A., Luqmani R.A., Richards N.T., Howie A.J., Emery P., et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 90 (1997) 401-409
11. Newburger J., Takahashi M., Burns J., Beiser A.S., Chung K.J., Duffy C.E., et al. The treatment of Kawasaki syndrome with intravenous gammaglobulins. N Engl J Med 315 (1986) 341-347
12. Jayne D.R., Chapel H., Adu D., Misbah S., O'Donoghue D., Scott D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93 (2000) 433-439
13. Jayne D.R., Esnault V.L., and Lockwood C.M. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 6 (1993) 207-219
14. Jayne D.R., and Lockwood C.M. Intravenous immunoglobulins as sole therapy for systemic vasculitis. Br J Rheumatol 35 (1996) 1150-1153
15. Martinez V., Pagnoux C., Mahr A., Mouthon L., and Guillevin L. Vascularites. elGFdEd, Intravenous immunoglobulins for relapses of ANCA-associated systemic vasculitides : final analysis of a prospective, open and multicenter trial (2005), American College of Rheumatology, San Diego (poster1752)
16. De Groot K., Rasmussen N., Bacon P.A., Tervaert J.W., Feighery C., Gregorini G., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 2461-2469
17. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
18. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41 (2002) 1126-1132
19. Specks U., Fervenza F.C., McDonald T.J., and Hogan M.C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44 (2001) 2836-2840
20. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262-268
21. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., and Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173 (2006) 180-187
22. Aries P.M., Hellmich B., Both M., Nolle B., Voswinkel J., Holl-Ulrich K., et al. Lack of efficacy of Rituximab in Wegener's Granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65 (2005) 853-858
23. Cheung C.M., Murray P.I., and Savage C.O. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 89 (2005) 1542
24. Ferraro A.J., Day C.J., Drayson M.T., and Savage C.O. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 20 (2005) 622-625
25. Jayne D., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F., Guillevin L., et al. Randomised trial of plasma exchange versus methyl prednisolone for severe renal vasculitis. submitted (2005)
26. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108 (2001) 184-190
27. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
28. Tatsis E., Schnabel A., and Gross W.L. Interferon-α treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 129 (1998) 370-374
29. Winchester D.E., Jacob A., and Murphy T. Omalizumab for asthma. N Engl J Med 355 (2006) 1281-1282
30. Metzler C., Lamprecht P., Hellmich B., Reuter M., Arlt A.C., and Gross W.L. Leucoencephalopathy after treatment of Churg-Strauss syndrome with interferon-α. Ann Rheum Dis 64 (2005) 1242-1243